Osteosarcoma Clinical Trial in Dogs

Summary: To assess the effectiveness of cryoablation and an investigational immunotherapy to treat osteosarcoma of the appendicular skeleton. Cryoablation is a technique to freeze tumors that may kill the tumor, alleviate pain, and assist the body in rejecting cancer that has spread.

Funding and Support: The pet owner is responsible for the cost of obtaining a diagnosis of osteosarcoma. Cryotherapy and/or immunotherapy and CT evaluations for cancer spread are fully funded. Amputation after treatment in the clinical trial is encouraged. Owners may also pursue subsequent chemotherapy treatment, if desired, at their own expense.

Trial Eligibility: Dogs of any breed, sex, and age are eligible.

Inclusion Criteria:
• Histopathological confirmation of osteosarcoma.
• Systemically healthy other than diagnosis of osteosarcoma.
• No prior treatment for osteosarcoma or chemotherapy for other cancers.
• The dog’s owner has the ability to understand and sign a written informed consent document and the willingness to comply with study protocol.
• Other restrictions may apply. Please call for details.

Exclusion Criteria:
• Dogs who have previously received chemotherapy or other investigational agents.
• Life-threatening medical or immunosuppressive illness unrelated to cancer.
• Dog who is participating in another study.

Trial Timeline: Eligible dogs will receive a CT scan and will receive cryotherapy alone, two doses of tumor-injected immunotherapy, or cryotherapy combined with immunotherapy. Amputation is recommended at approximately 2 weeks after treatment. CT scans will be obtained at 3, 6, and 12 months after treatment.

If interested, please contact:
The Center for Image-Guided Animal Therapy
Johns Hopkins University
Dara Kraitchman, VMD, PhD
Rebecca Krimins, DVM, MS
Email: cigat@jhmi.edu
Telephone: 410-502-7325